Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06820515 · ClinicalTrials.gov registry record
ATHNdataset Registry
A clinical trial, sponsored by American Thrombosis and Hemostasis Network.
- Recruiting
- Registry status
- 200,000
- Enrollment target
NCT06820515: Recruiting study, sponsored by American Thrombosis and Hemostasis Network.
NCT06820515 is a clinical trial that is actively recruiting participants, run by American Thrombosis and Hemostasis Network. The registered enrollment target is 200,000 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06820515 is actively recruiting participants, sponsored by American Thrombosis and Hemostasis Network.
- RECRUITING
- Registry status
- 200,000 participants
- Enrollment target
Study Summary
The Hemophilia Treatment Center (HTC) where you receive care is working with The American Thrombosis and Hemostasis Network (ATHN) to look at the quality of life of people with blood disorders and problems. Doctors, scientists, policymakers, and other health care providers need a large amount of information from a lot of people to answer scientific, public health, and policy questions about better ways to treat blood disorders. They will use the information from the ATHNdataset to answer these questions.
Primary Outcome
The ATHNdataset Registry objective is to develop a secure, comprehensive registry of real-world clinical data to support standardized comprehensive health information for persons living with blood disorders and public health reporting for the blood disorders community
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200,000 participants |
| Start Date | 2024-10-25 |
| Est. Completion | 2055-10-31 |
What NCT06820515 shows while recruiting
NCT06820515 is an observational study that tracks outcomes without assigning an intervention. Its 200,000 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT06820515 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06820515 about?
NCT06820515 is a clinical study titled "ATHNdataset Registry". The Hemophilia Treatment Center (HTC) where you receive care is working with The American Thrombosis and Hemostasis Network (ATHN) to look at the quality of life of people with blood disorders and problems. Doctors, scientists, policymakers, and other health care providers need a large amount of in...
What is the current status of trial NCT06820515?
This trial is currently recruiting. The enrollment target is 200,000 participants. The study started on 2024-10-25. Estimated completion is 2055-10-31.
Who is sponsoring clinical trial NCT06820515?
This trial is sponsored by American Thrombosis and Hemostasis Network, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06090578 · 180,000 participants · NA
TabCAT Brain Health Assessment in Primary Care
- NCT06917339 · 156,000 participants
Retrospective Analyses of TrakStar Database
- NCT06232551 · 152,000 participants · NA
Alerting Providers at Patient Hospital Discharge to Consider Prescribing Rivaroxaban to Reduce Venous Thromboembolism
- NCT04735835 · 250,000 participants · NA
Personalized Responses to Dietary Composition Trial 3
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI